fascaplysine has been researched along with bibw 2992 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funovics, M; Hamilton, G; Hochmair, M; Neumayer, C; Plangger, A; Rath, B; Zeillinger, R | 1 |
1 other study(ies) available for fascaplysine and bibw 2992
| Article | Year |
|---|---|
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin-Dependent Kinase 4; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |